Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474931 | 0.85 | POLB (0.41) | POLBL3MBTL1PREPACEREN | |
| SCHEMBL3340426 | 0.85 | POLB (0.41) | POLBL3MBTL1PREPACEREN | |
| SCHEMBL4936887 | 0.85 | POLB (0.41) | POLBL3MBTL1PREPACEREN | |
| SCHEMBL14609170 | 0.81 | DPP4 (0.41) | POLBL3MBTL1PREPDPP4FAP | |
| SCHEMBL14273993 | 0.81 | POLB (0.43) | POLBL3MBTL1PREPDPP4FAP | |
| SCHEMBL23001260 | 0.79 | POLB (0.39) | POLBL3MBTL1PREPACEDPP4 | |
| SCHEMBL4041080 | 0.79 | CHRM2 (0.44) | — | |
| SCHEMBL1820000 | 0.79 | CHRM2 (0.44) | — | |
| SCHEMBL3515949 | 0.79 | POLB (0.35) | POLBL3MBTL1PREPACEREN | |
| SCHEMBL2983461 | 0.79 | POLB (0.35) | POLBL3MBTL1PREPACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105283553-B | Protein-enriched microvesicles and methods of making and using same | 克隆技术实验室有限公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20200256858-A1 | Modifiable Chemical Inducers of Proximity and Methods of Using the Same | TAKARA BIO USA, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10634668-B2 | Modifiable chemical inducers of proximity and methods of using the same | TAKARA BIO USA, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20140080137-A1 | MODIFIABLE CHEMICAL INDUCERS OF PROXIMITY AND METHODS OF USING THE SAME | TAKARA BIO USA, INC. | 2014-03-20 | — | — | US | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-0888303-B1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD PHARMA INC (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-1838288-A1 | THERAPEUTIC MATERIALS AND METHODS | ARIAD GENE THERAPEUTICS, INC. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20030036654-A1 | Synthetic multimerizing agents | HOLT DENNIS A (US) | 2003-02-20 | — | — | US | disclosed |
| US-20020161240-A1 | Synthetic multimerizing agents | ARIAD GENE THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6133456-A | DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0888303-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0776327-A4 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS INC (US) | 1997-12-10 | — | — | EP | disclosed |
| WO-1997031899-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERISING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031898-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| EP-0776327-A1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996006097-A1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS, INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161240-A1 | Synthetic multimerizing agents | SSB, F13B, LCP2 | POLB 2530/4885L3MBTL1 537/4885PREP 2815/4885 |
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | POLB 3203/4885L3MBTL1 788/4885PREP 1264/4885 |
| US-20030036654-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | POLB 3620/4885L3MBTL1 1758/4885PREP 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.